[ CAS No. 1408074-89-4 ] {[proInfo.proName]}

Name: 1408074-89-4|cis-3-((tert-Butyldimethylsilyl)oxy)cyclobutanol|97%
Brand: Ambeed
SKU: A223977
Price: 255.0 USD
Availability: InStock
Rating: 99 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1408074-89-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1408074-89-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1408074-89-4 ]

SDS Specification

Alternatived Products of [ 1408074-89-4 ]

Product Details of [ 1408074-89-4 ]

CAS No. :	1408074-89-4	MDL No. :	MFCD23105930
Formula :	C₁₀H₂₂O₂Si	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	ILGIKHCMCDNBSK-UHFFFAOYSA-N
M.W :	202.37	Pubchem ID :	57515873
Synonyms :

Safety of [ 1408074-89-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1408074-89-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1408074-89-4 ]

[ 1408074-89-4 ] Synthesis Path-Downstream 1~11

1
[ 1408074-89-4 ]
[ 458560-71-9 ]
[ 1703766-05-5 ]

Yield	Reaction Conditions	Operation in experiment
95%	Stage #1: (1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol With sodium hydride In tetrahydrofuran; N,N-dimethyl-formamide for 0.5h; Cooling with ice; Stage #2: (S)-3-benzyl-4-methyl-[1,2,3]-oxathiazolidine-2,2-dioxide In tetrahydrofuran; N,N-dimethyl-formamide at 20℃; for 2h; Cooling with ice; Stage #3: With hydrogenchloride In water at 20℃; for 1h; Cooling with ice;	6.1 Step 1 Preparation of Compound a21 Step 1 Preparation of Compound a21 (0436) Compounds a20 (0.53g, 2.6mmol) was dissolved in DMF (5.0mL) and THF (2.5mL), sodium hydride (0.13g, 3.3mmol) was added under ice-cooling and the mixture was stirred for 30 minutes under ice-cooling. THF (2.5mL) solution of (S) -3-benzyl-4-methyl-1, 2, 3-oxathiazolidine-2, 2-dioxide (0.50g, 2.2mmol) was to the reaction solution under ice-cooling, and the mixture was stirred at room temperature for 2 hours. 2mole / L hydrochloric acid aqueous solution (10mL) was added to the reaction solution under ice-cooling, and the mixture was stirred at room temperature for 1 hour. 2mol / L sodium hydroxide solution (10mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate. The reaction solvent was distilled off under reduced pressure, and the obtained residue was purified by amino silica gel column chromatography (chloroform-methanol) to give Compound a21 (0.53g, 95% yield). 1H-NMR (CDCl3) δ: 1.06 (d, J = 6.3 Hz, 3H), 1.91-1.78 (m, 2H), 2.76-2.62 (m, 2H), 2.95-2.85 (m, 1H) 3.32- 3.17 (m, 2H), 3.56-3.46 (m, 1H), 3.78-3.67 (m, 1H), 3.96-3.83 (m, 2H), 7.37-7.21 (m, 5H). [M + H] = 236.5, Method Condition 4: retention time 0.66 minutes

Reference： [1]Current Patent Assignee: SHIONOGI & CO., LTD. - EP3059225, 2016, A1 Location in patent: Paragraph 0436

2
[ 2173375-57-8 ]
[ 1408074-89-4 ]

Yield	Reaction Conditions	Operation in experiment
84%	With palladium 10% on activated carbon; hydrogen In ethanol at 25℃; for 3h;	2 Step 2 To a solution of (3-benzyloxycyclobutoxy)-tert-butyl-dimethyl-silane (7.2 g, 24.62 mmol, 1 eq) in ethanol (50 mL) was added 10% palladium on activated carbon catalyst (500 mg) under nitrogen. The suspension was degassed under vacuum and purged with hydrogen 3 times. The mixture was stirred under hydrogen (50 psi) at 25 °C for 3 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. Compound 3-[tert- butyl(dimethyl)silyl]oxycyclobutanol (4.2 g, 20.75 mmol, 84% yield) was obtained as a light yellow oil.
88 mg	With ammonium formate; palladium In ethanol at 20 - 80℃;	26 Intermediate 26: syn-3-[ferf-butyl(dimethyl)silyl1oxycvclobutanol To a solution of syn-(3-benzyloxycyclobutoxy)-tert-butyl-dimethyl-silane (225 mg, 0.77 mmol, Intermediate 24) in EtOH (20 mL), palladium (16 mg, 0.15 mmol) and ammonium formate (477 mg, 7.7mmol) were added. The suspension was stirred at reflux for 5 h and at r.t. overnight. Then, further palladium (16 mg, 0.15 mmol) and ammonia formate (477 mg, 7.7 mmol) were added and the reaction heated at 80 °C for 7 h and at r.t. for the weekend. The suspension was filtered through cellulose microcrystalline and concentrated under reduced pressure. The crude was purified by flash chromatography (Biotage system) on silica gel using a SNAP 25 g as column and cHex/EtOAc from 99:1 to 50:50 as eluent, affording the title compound sy/i-3-[tert- butyl(dimethyl)silyl]oxycyclobutanol (88 mg) as a colourless oil. HPLC 3 min RT: 2.35 min [M+H+] : 203.

Reference： [1]Current Patent Assignee: ARVINAS - WO2021/11913, 2021, A1 Location in patent: Paragraph 1541; 1542
[2]Current Patent Assignee: AUTIFONY THERAPEUTICS LIMITED - WO2018/20263, 2018, A1 Location in patent: Page/Page column 107

3
[ 4910-04-7 ]
(1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol [ No CAS ]
3-tert-butyl-4-[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy] benzonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
131 mg	With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; at 20.0℃;	To a solution of syn-3-[tert-butyl(dimethyl)silyl]oxycyclobutanol (85 mg, 0.42 mmol, Intermediate 26) in THF (5 mL), 3-tert-butyl-4-hydroxy-benzonitrile (88 mg, 0.50 mmol), triphenyl phosphine (165mg, 0.63mmol) and DIAD (102 mg, 0.50 mmol) were added. The reaction was stirred at r.t. overnight. Then the solvent was evaporated under reduced pressure and the crude was purified by flash chromatography (Biotage system) on silica gel using a SNAP 50 g as column and cHex/EtOAc from 99:1 to 80:20 as eluent, affording the title compound (131mg) as a pale yellow solid. HPLC 3 min RT: 3.32 min [M+H+]: 360.

Reference： [1]Patent: WO2018/20263,2018,A1 .Location in patent: Page/Page column 108

4
[ 1261648-89-8 ]
3-[tert-butyl(dimethyl)silyl]oxycyclobutanol [ No CAS ]
4-[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]-2-(trifluoromethoxy)benzonitrile [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
162 mg	With di-isopropyl azodicarboxylate; triphenylphosphine; In tetrahydrofuran; at 20.0℃;	<strong>[1261648-89-8]4-hydroxy-2-(trifluoromethoxy)benzonitrile</strong> (80 mg, 0.39mmol) was dissolved in THF (8 mL), then syn-3-[tert-butyl(dimethyl)silyl]oxycyclobutanol (88 mg, 0.43 mmol, Intermediate 26), triphenyl phosphine (124 mg, 0.47 mmol) and DIAD (88 mg, 0.43 mmol) were added. The reaction mixture was stirred overnight at r.t., then concentrated. The crude was purified by flash chromatography (Biotage system) using two SNAP 10 g as column and cHex/EtOAc (from 10:0 to 1:1) affording the title compound (162 mg) as a yellow oil. HPLC 3 min RT: 3.10 min.

Reference： [1]Patent: WO2018/20263,2018,A1 .Location in patent: Page/Page column 109

5
[ 5292-43-3 ]
[ 1408074-89-4 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: (1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol With sodium hydride In tetrahydrofuran at 0℃; for 0.5h; Stage #2: bromoacetic acid <i>tert</i>-butyl ester In tetrahydrofuran at 20℃; for 12h;	35 tert-butyl 2-[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]acetate: To a mixture of 3- [tertbutyl(dimethyl)silyljoxycyclobutanol (3.5 g, 17.3 mmol) in THF (30 mL) at 0 °C was added NaH (830 mg, 20.8 mmol, 60% purity). After 30 mi tert-butyl 2-bromoacetate (3.71 g, 19.0 mmol) was added, and the mixture was stirred for 12 h at rt. The mixture was poured into aq. NH4C1 (50 mL) and EtOAc (25 mL) was added. The layers were separated and the aqueous phase was extracted with EtOAc (3 x 15 mL). The combined organic phases were washed with brine (15 mL), dried with anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silicagel column chromatography (PE:EtOAc = 100:1 to 1:1) to provide tert-butyl 2-[3-[tert-butyl (dimethyl)silyljoxycyclobutoxyj acetate.

Reference： [1]Current Patent Assignee: DENALI THERAPEUTICS INC - WO2019/183589, 2019, A1 Location in patent: Paragraph 0303

6
[ 32315-10-9 ]
[ 1408074-89-4 ]
[ 2415380-29-7 ]
[ 2415381-74-5 ]

Yield	Reaction Conditions	Operation in experiment
69.6%	With N-ethyl-N,N-diisopropylamine In dichloromethane at 0℃; for 2h;	185.1 Step 1: tert-Butyl 7-(8-((tert-butoxycarbonyl)amino)-3-((((1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutoxy)carbonyl)amino)-7-fluoroisoquinolin-6-yl)-8-methyl-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate To a solution of tert-butyl 7-[3-amino-8-(tert-butoxycarbonylamino)-7-fluoro-6-isoquinolyl]-8-methyl-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate (180 mg, 0.34 mmol), (1s,3 s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol (130 mg, 0.64 mmol) and DIEA (132 mg, 1.02 mmol) in dichloromethane (18 mL) was added triphosgene (150 mg, 0.51 mmol) at 0° C. The resulting solution was stirred for 2 hours at 0° C. The reaction solution was concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with methanol/dichloromethane (7%) to afford tert-butyl 7-(8-((tert-butoxycarbonyl)amino)-3-((((1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutoxy)carbonyl)amino)-7-fluoroisoquinolin-6-yl)-8-methyl-3,4-dihydro-1,5-naphthyridine-1(2H)-carboxylate (200 mg, 0.239 mmol, 69.6% yield) as a yellow solid. LCMS (ESI) [M+H]+=752.0.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2020/108075, 2020, A1 Location in patent: Paragraph 1082; 1083

7
[ 32315-10-9 ]
[ 1408074-89-4 ]
[ 2415382-13-5 ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
51.4%	With N-ethyl-N,N-diisopropylamine In dichloromethane at 0℃; for 1h;	205.10 Step 10: tert-Butyl 5-[8-(tert-butoxycarbonylamino)-3-[[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]carbonylamino]-7-fluoro-6-isoquinolyl]-4-methyl-1,1a,2,7b-tetrahydrocyclopropa[c][1,5]naphthyridine-3-carboxylate To a solution of tert-butyl 5-[3-amino-8-(tert-butoxycarbonylamino)-7-fluoro-6-isoquinolyl]-4-methyl-1,1a,2,7b-tetrahydrocyclopropa[c][1,5]naphthyridine-3-carboxylate (300 mg, 0.56 mmol) and 3-[tert-butyl(dimethyl)silyl]oxycyclobutanol (250 mg, 1.24 mmol) in dichloromethane (30 mL) was added DIEA (730 mg, 5.66 mmol) at room temperature. Then triphosgene (140 mg, 0.47 mmol) was added . Tthe mixture was stirred at 0° C. for 1 hour. The residue was purified by flash chromatography on silica gel eluting with petroleum ether/ethyl acetate (1/1) to afford tert-butyl 5-[8-(tert-butoxycarbonylamino)-3-[[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]carbonylamino]-7-fluoro-6-isoquinolyl]-4-methyl-1,1a,2,7b-tetrahydrocyclopropa[c][1,5]naphthyridine-3-carboxylate (220 mg, 0.288 mmol, 51.4% yield) as a yellow solid. LCMS (ESI) [M+H]+=764.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2020/108075, 2020, A1 Location in patent: Paragraph 1252; 1253

8
[ 32315-10-9 ]
[ 1408074-89-4 ]
[ 2415382-21-5 ]
[ 2415382-22-6 ]

Yield	Reaction Conditions	Operation in experiment
83.4%	With N-ethyl-N,N-diisopropylamine In dichloromethane at 0℃; for 2h;	206.8 Step 8: tert-Butyl-7-[8-(tert-butoxycarbonyl amino)-3-[[3-[tert-butyl (dimethyl)silyl]oxycyclobutoxy]-carbonylamino]-7-fluoro-6-isoquinolyl]-3,8-dimethyl-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate A solution of tert-butyl 7-[3-amino-8-(tert-butoxycarbonylamino)-7-fluoro-6-isoquinolyl]-3,8-dimethyl-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate (240 mg, 0.45 mmol), cis-3[tert-butyl(dimethyl)silyl]oxycyclobutanol (180 mg, 0.89 mmol) and N,N-diisopropylethylamine (575 mg, 4.46 mmol) in dichloromethane (18 mL) was stirred at 0° C. Then a solution of triphosgene (132 mg, 0.44 mmol) in dichloromethane (2 mL) was added dropwise. The mixture was stirred at 0° C. for 2 hours. The resulting mixture was diluted with dichloromethane and washed with water. The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified by flash chromatography on silica gel eluting with dichloromethane/methanol (19:1) to afford cis-tert-butyl-7-[8-(tert-butoxycarbonylamino)-3-[[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]carbonylamino]-7-fluoro-6-isoquinolyl]-3,8-dimethyl-3,4-dihydro-2H-1,5-naphthyridine-1-carboxylate (300 mg, 0.372 mmol, 83.4% yield) as a brown solid. LCMS (ESI) [M+H]+=766.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2020/108075, 2020, A1 Location in patent: Paragraph 1273; 1274

9
[ 32315-10-9 ]
[ 1408074-89-4 ]
[ CAS Unavailable ]
[ CAS Unavailable ]

Yield	Reaction Conditions	Operation in experiment
53.7%	Stage #1: (1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol; tert-butyl 7-(3-amino-8-((tert-butoxycarbonyl)amino)-7-fluoroisoquinolin-6-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 2h; Stage #2: bis(trichloromethyl) carbonate In dichloromethane at 0℃; for 1h;	156.1 Step 1: tert-Butyl 7-(8-((tert-butoxycarbonyl)amino)-7-fluoro-3-((((1s,3s)-3-hydroxycyclobutoxy)carbonyl)amino)isoquinolin-6-yl)-8-methyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate A solution of tert-butyl 7-[3-amino-8-(tert-butoxycarbonylamino)-7-fluoro-6-isoquinolyl]-8-methyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-1-carboxylate (300 mg, 0.57 mmol), (1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol (230 mg, 1.14 mmol) and DIEA (368.86 mg, 2.85 mmol) in dichloromethane (2 mL) was stirred at room temperature for 2 hours. Then triphosgene (169.4 mg, 0.57 mmol) was added. The reaction mixture was then stirred at 0° C. for 1 hour. The reaction mixture was concentrated under vacuum. The residue was purified by reverse phase chromatography (acetonitrile 0-60/ 0.1% NH4HCO3 in water) to afford tert-butyl 7-[8-(tert-butoxycarbonylamino)-3-[[3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]carbonylamino]-7-fluoro-6-isoquinolyl]-8-methyl-2,3-dihydropyrido[2,3-b][1,4]oxazine-1-carboxylate (150 mg, 0.23 mmol, 53.7% yield) as a light yellow solid. LC/MS (ESI): [M+H]+=640.3.

Reference： [1]Current Patent Assignee: ROCHE HOLDING AG - US2020/108075, 2020, A1 Location in patent: Paragraph 0867; 0868

10
[ 1408074-89-4 ]
[ 2573231-13-5 ]
[ 2573231-49-7 ]
[ 2573232-74-1 ]

Yield	Reaction Conditions	Operation in experiment
1: 53% 2: 31%	With potassium <i>tert</i>-butylate In tetrahydrofuran at 20℃; for 2h;	18.1 Step 1: Ethyl-4-amino-2-(3-cyanophenyl)-6-[(1s,3s)-3-[(tert- butyldimethylsilyl)oxy]cyclobutoxy] pyrimidine-5-carboxylate A solution of ethyl 4-amino-6-chloro-2-(3-cyanophenyl)pyrimidine-5- carboxylate (Example 5 step 1) (500 mg, 1.65 mmol), (1s,3s)-3-[(tert- butyldimethylsilyl)oxy]cyclobutan-1-ol (501 mg, 2.48 mmol) and 1M potassium t-butoxide in THF (1.82 mL, 1.82 mmol) in THF (10 mL) was stirred at room temperature for 2 h. The resulting mixture was diluted with water (20 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were filtered through a phase separating cartridge and concentrated in vacuo. The resulting orange gum was triturated in ether (20 mL), the solid removed by filtration, and the filtrate concentrated in vacuo. The resulting yellow gum was purified by chromatography on silica eluting with 0-100% EtOAc in heptane to afford a mixture of to afford a mixture of the title compound and [(1s, 3s)-3-[tert-butyl(dimethyl)silyl]oxycyclobutyl] 4- amino-6-[(1s, 3s)-3-[tert-butyl(dimethyl)silyl]oxycyclobutoxy]-2-(3-cyanophenyl)pyrimidine-5- carboxylate as a yellow oil. LC-MS (Method 2A): Rt 2.08 mins; MS m/z 469.3 = [M+H]+ ethyl ester (53%) and Rt 2.39 min, MS m/z 625.4 = [M+H]+ trans esterified product (31%) 1H NMR (500 MHz, Chloroform-d) d 8.65 (s, 1H), 8.58 (dd, J = 7.8, 1.3 Hz, 1H), 7.74 (dt, J = 7.8, 1.3 Hz, 1H), 7.56 (t, J = 7.8 Hz, 1H), 4.98 (p, J = 7.3 Hz, 1H), 4.73 (p, J = 7.3 Hz, 0.3H), 4.58 (q, J = 6.5, 6.0 Hz, 0.2H), 4.35 (q, J = 7.1 Hz, 2H), 4.03 (q, J = 7.1 Hz, 0.3H), 3.83 (p, J = 7.2 Hz, 1H), 2.98- 2.91 (m, 2H), 2.87 (dtd, J = 9.5, 6.7, 3.0 Hz, 0.7H), 2.71 (dddd, J = 12.1, 9.4, 6.0, 2.8 Hz, 2H), 2.27- 2.16 (m, 3H), 1.93- 1.85 (m, 2H), 1.42 (t, J = 7.1 Hz, 2H), 0.90 (d, J = 3.1 Hz, 11H), 0.88 (s, 8H), 0.08 (s, 6H), 0.07 (s, 2H), 0.03 (s, 4H).

Reference： [1]Current Patent Assignee: ADORX THERAPEUTICS - WO2020/260857, 2020, A1 Location in patent: Paragraph 00302

11
[ 1408074-89-4 ]
[ 824-94-2 ]
[ 2589698-00-8 ]

Yield	Reaction Conditions	Operation in experiment
69%	Stage #1: (1s,3s)-3-((tert-butyldimethylsilyl)oxy)cyclobutan-1-ol With sodium hydride In N,N-dimethyl-formamide at 0℃; for 1h; Inert atmosphere; Stage #2: p-methoxybenzyl chloride In N,N-dimethyl-formamide at 25℃; for 16h; Inert atmosphere;	3 Step 3 To a mixture of 60% sodium hydride (899 mg, 22.48 mmol, 1.3 eq) in N,N- dimethylformamide (50 mL) was added 3-[tertbutyl(dimethyl)silyl]oxycyclobutanol (3.5 g, 17.30 mmol, 1 eq) at 0 °C under nitrogen. After 1 h, 4-methoxybenzyl chloride (3.52 g, 22.48 mmol, 3.06 mL, 1.3 eq) was added. The reaction mixture was stirred at 25°C for another 16 h. The reaction mixture was quenched by the addition of water (50 mL), and extracted with ethyl acetate (100 mL x 3). The combined organic layers were washed with brine (100 mL x 3), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 200/1 to 100/1). Compound tert-butyl-[3-[(4-methoxyphenyl)methoxy]cyclobutoxy]-dimethyl-silane (3.9 g, 12.09 mmol, 69% yield) was obtained as a colorless oil.

Reference： [1]Current Patent Assignee: ARVINAS - WO2021/11913, 2021, A1 Location in patent: Paragraph 1543; 1544

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 1408074-89-4 ]

Organosilicon

[ 1408075-44-4 ]

trans-3-((tert-Butyldimethylsilyl)oxy)cyclobutanol

Similarity: 1.00

[ 1394119-83-5 ]

3-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]cyclobutanemethanol

Similarity: 0.90

[ 959749-93-0 ]

(cis-3-((tert-Butyldimethylsilyl)oxy)cyclobutyl)methanol

Similarity: 0.90

[ 1403767-02-1 ]

(trans-3-((tert-Butyldimethylsilyl)oxy)cyclobutyl)methanol

Similarity: 0.90

[ 126931-29-1 ]

4-((tert-Butyldimethylsilyl)oxy)cyclohexanol

Similarity: 0.90

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 1408074-89-4 ] {[proInfo.proName]}

Quality Control of [ 1408074-89-4 ]

Related Doc. of [ 1408074-89-4 ]

Product Details of [ 1408074-89-4 ]

Safety of [ 1408074-89-4 ]

Application In Synthesis of [ 1408074-89-4 ]

[ 1408074-89-4 ] Synthesis Path-Downstream 1~11

Related Functional Groups of [ 1408074-89-4 ]

Organosilicon

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 1408074-89-4 ]